Qingsong Liu

High Magnetic Field Laboratory
Hefei, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Discovery of Dihydropyrimido-Pyrimidine-Based Bone Marrow Tyrosine Kinase Gene in Chromosome X Protein Proteolysis-Targeting Chimeras for the Treatment of Prostate Cancer.

Discovery of Dihydropyrimido-Pyrimidine-Based Bone Marrow Tyrosine Kinase Gene in Chromosome X Protein Proteolysis-Targeting Chimeras for the Treatment of Prostate Cancer.

Journal: ACS medicinal chemistry letters

Published: March 07, 2026

Discovery of pyrazole derivative IHMT-140 as a pancreatic cancer therapeutic agent via dual mechanisms DDR1 inhibition and methuosis induction.

Discovery of pyrazole derivative IHMT-140 as a pancreatic cancer therapeutic agent via dual mechanisms DDR1 inhibition and methuosis induction.

Journal: Journal of advanced research

Published: February 14, 2026

Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Journal: Journal of medicinal chemistry

Published: October 13, 2025

Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease.

Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease.

Journal: Journal of medicinal chemistry

Published: October 13, 2025

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy.

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy.

Journal: iScience

Published: September 17, 2025

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation.

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 27, 2025

TCCA/PhSH-mediated regioselective hydroethoxylation and hydromethoxylation of allenamides via a radical process.

TCCA/PhSH-mediated regioselective hydroethoxylation and hydromethoxylation of allenamides via a radical process.

Journal: Organic & biomolecular chemistry

Published: August 20, 2025

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: August 08, 2025

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis.

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis.

Journal: Signal transduction and targeted therapy

Published: June 06, 2025

Discovery of IHMT-15130 as a Highly Potent Irreversible BMX Inhibitor for the Treatment of Myocardial Hypertrophy and Remodeling.

Discovery of IHMT-15130 as a Highly Potent Irreversible BMX Inhibitor for the Treatment of Myocardial Hypertrophy and Remodeling.

Journal: ACS chemical biology

Published: May 19, 2025

Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

Journal: Journal of medicinal chemistry

Published: April 08, 2025

Shufeng Jiedu Granule against mild COVID-19: Protocol of the randomized, double-blind, placebo-controlled, multi-center heal-COVID phase III study.

Shufeng Jiedu Granule against mild COVID-19: Protocol of the randomized, double-blind, placebo-controlled, multi-center heal-COVID phase III study.

Journal: Chinese herbal medicines

Published: October 31, 2024

Showing 1-12 of 126

Last Updated: 09/26/2026